Stony Brook, NY. (PRWEB) May 21, 2014 -- Applied DNA Sciences, Inc. (OTCQB: APDN), (Twitter: @APDN), a biotechnology firm that provides DNA-based authentication and security solutions, will present at the Marcum MicroCap Conference in New York City on May 29, 2014.
Management will be reviewing the company's operations and business strategy during their presentation that will take place at 11:00 AM ET in the Winter Garden Room. Members of the management team will also be available to meet with the investment community during one-on-one sessions being held at the conference.
Anyone interested in meeting with management that day can contact their representative at Marcum.
The conference will be held at:
Grand Hyatt New York
109 E 42nd Street
New York, NY 10017
See more at: http://marcumllp.com/MicroCap/agenda
About Applied DNA Sciences
APDN is a provider of botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA describes the uncopyable marker that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of products such as DNAnet®, our anti-theft product, SigNature® T, targeted toward textiles, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators.
The statements made by APDN may be forward-looking in nature. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K filed on December 20, 2013 (amended on May 1, 2014) and our subsequent quarterly reports on Form 10-Q/A (for the quarterly period ended December 31, 2013) and Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.
Mitchell Miller, Applied DNA Sciences, http://www.adnas.com, +1 (631) 240-8818, [email protected]